PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.27% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.48%, a 5.16% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.26%.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.01%.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.48%, a 4.48% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.69%, a 0.86% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.65%, a 7.14% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.34%, a 233.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.27% 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | 4.48% 10-K · filed 2026-03-06 | |||
| 2025-09-30 | 4.48% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 4.48% 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | 4.48% 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 4.69% 10-K · filed 2026-03-06 | |||
| 2024-09-30 | 4.69% 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 4.69% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 4.26% 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 4.65% 10-K · filed 2026-03-06 | |||
| 2023-09-30 | 4.18% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 3.95% 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | 4.34% 10-K · filed 2025-03-03 | |||
| 2022-09-30 | 3.42% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 2.93% 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 2.01% 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 1.30% 10-K · filed 2024-02-29 | |||
| 2021-09-30 | 1.22% 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 1.22% 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | 1.51% 10-K · filed 2023-03-01 | |||
| 2020-09-30 | 1.51% 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | 2.51% 10-K · filed 2022-03-01 | |||
| 2018-12-31 | 2.83% 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |